Shuttle Pharmaceuticals Holdings (SHPH) Income towards Parent Company (2021 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Income towards Parent Company of -$2.5 million for Q1 2026, up 20.14% year-over-year from -$2.1 million in Q1 2025, and up 13.6% quarter-over-quarter from -$2.9 million in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Income towards Parent Company (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$2.5 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 20.14% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$12.0 million (down 28.06% YoY), while the FY2025 annual figure was -$19.7 million, down 54.97% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$2.5 million, up from -$2.9 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$368462.0 in Q2 2022, with the low at -$4.2 million in Q2 2025.
- The 5-year median for Income towards Parent Company is -$2.0 million (2023), against an average of -$2.1 million.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company sank 492.21% in 2022, then jumped 50.69% in 2024.
- Shuttle Pharmaceuticals Holdings' Income towards Parent Company stood at -$2.7 million in 2022, then gained by 19.01% to -$2.2 million in 2023, then surged by 50.69% to -$1.1 million in 2024, then sank by 168.25% to -$2.9 million in 2025, then rose by 13.6% to -$2.5 million in 2026.
- Business Quant data shows SHPH's Income towards Parent Company at -$2.5 million in Q1 2026, -$2.9 million in Q4 2025, and -$2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.83 Mn | 1.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.52 Mn |
| Dec 31, 2025 | -2.91 Mn |
| Sep 30, 2025 | -2.37 Mn |
| Jun 30, 2025 | -4.22 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -1.09 Mn |
| Sep 30, 2024 | -3.25 Mn |
| Jun 30, 2024 | -1.90 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Dec 31, 2023 | -2.20 Mn |
| Sep 30, 2023 | -1.78 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | -975,097.00 |
| Dec 31, 2022 | -2.72 Mn |
| Sep 30, 2022 | -998,425.00 |
| Jun 30, 2022 | -368,462.00 |
| Mar 31, 2022 | -681,839.00 |
| Dec 31, 2021 | -459,048.00 |
| Sep 30, 2021 | -216,961.00 |